Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole

Drug Metabolism and Disposition

Volumn 28, Issue 1, 2000, Pages 58-64

  Äbelö, Angela ^a   Andersson, Tommy B ^a   Bredberg, Ulf ^a   Skånberg, Inger ^b   Weidolf, Lars ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; CYTOCHROME P450 2C19; OMEPRAZOLE DERIVATIVE;

ARTICLE; CALCULATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOMER; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; STEREOCHEMISTRY;

ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 0033957504     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors-focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31:9-28.
2. Andersson T, Holmberg J, Röhss K and Walan A (1998) Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 45:369-375.
3. Andersson T, Lagerström PO, Miners JO, Veronese ME, Weidolf L and Birkett DJ (1993a) High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism. J Chromatogr 619:291-297.
4. Andersson T, Miners JO, Tassaneeyakul W, Tassaneeyakul W, Veronese ME and Meyer UAB (1993b) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36:521-530.
5. Andersson T, Miners JO, Veronese ME and Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38:131-137.
6. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T and Ishizaki T (1993) Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266:52-59.
7. Ernster L, Siekevitz P and Palada GE (1962) Enzyme-structure relationships in the endoplasmic reticutum of rat liver. J Cell Biol 15:541-562.
8. Ibeanu GC, Ghanayem I, Linko P, Li L, Pedersen G and Goldstein JA (1996) Identification of residues 99, 220 and 221 of human cytochrome P450 2C19 as key determinants of omeprazole hydroxylase activity. J Biol Chem 271:12496-12501.
9. Karol MD, Granneman GR and Alexander K (1995) Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography. J Chromatogr 668:182-186.
10. Katsuki H, Yagi H, Arimori K, Nakamura C, Nakano M, Katafuchi S, Fujioka Y and Fujiyama S (1996) Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res 13:611-615.
11. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
12. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2370-2378.
13. Pearce RE, Rodrigues AD, Goldstein JA and Parkinson A (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805-816.
14. Pichard L, Curi-Pedrosa R, Bonfils C, Jacoz-Aigrain E, Domergue J, Joyeux H, Cosme J, Guengerich P and Maurel P (1995) Oxidative metabolism of lansoprazole by human liver cytochromes P450. J Pharmacol Exp Ther 47:410-418.
15. Sanz EJ, Villèn T, Alm C and Bertilsson L (1989) Phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 45:495-499.
16. Schwab GE, Raucy JL and Johnsson EF (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol Pharmacol 33:493-499.
17. Shimada S, Yamazaki H, Mimura M, Inui Y and Guengerich P (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
18. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzales FJ, Gelboin HV and Korzekwa KR (1994) Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
19. Simon WA (1995) Pantoprazole-which cytochrome P450 isoenzymes are involved in its biotransformation Gut 37(Suppl 2):A135.
20. Smith DA, Ackland MJ and Jones BC (1997) Properties of cytochrome P450 isoenzymes and their substrates. Part 2: Properties of cytochrome P450 substrates. Drug Discovery Today 2:479-486.
21. Tanaka M, Yamazaki H, Hakusui H, Nakamichi N and Sekino H (1997) Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole-a preliminary study. Chirality 9:17-21.
22. Tybring G, Böttiger Y, Widén J and Bertilsson L (1997) Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 62:129-137.
23. Ueng YF, Kuwabara T, Chun YJ and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
24. von Unge S, Langer V and Sjölin L (1997) Stereochemical assignment of the enantiomers of omeprazole from X-ray analysis of a fenchyloxymethyl derivative of (+)-(R)-omeprazole. Tetrahedron: Asymmetry 8:1967-1970.
25. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich P and Shimada T (1997) Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434-442.